期刊文献+

RP-HPLC法同时测定人血清中氯吡格雷和阿司匹林的浓度 被引量:4

Determination of Clopidogrel and Aspirin in Human Blood Serum by RP-HPLC
原文传递
导出
摘要 目的:建立以反相高效液相色谱法同时测定人血清中氯吡格雷和阿司匹林浓度的方法。方法:色谱柱为Hypersil ODS C18,流动相为0.01mo·lL-1磷酸二氢钾溶液-甲醇(35∶65,磷酸调pH值至3),流速为1.0mL·min-1,检测波长为235nm,柱温为30℃。结果:氯吡格雷与阿司匹林血药浓度分别在0.25~16.0mg·L-1(r=0.9999)、0.125~8.0mg·L-1(r=0.9996)范围内线性关系良好;平均回收率分别为98.3%、99.6%,日内、日间RSD均<10%。结论:本方法简便、快速、灵敏度高,可用于人血清中氯吡格雷和阿司匹林浓度的检测与分析。 OBJECTIVE: To establish an RP-HPLC method for determination of clopidogrel and aspirin in human blood serum. METHODS: The separation was performed on Hypersil ODS C18 column. The mobile phase was 0.01 mol.L^-1 potassium dihydrogen phosphate-methanol (35:65)(adjust pH to 3 by phosphoric acid), with column temperature set at 30℃. The flow rate was 1.0 mL-min ^-1 and detection wavelength was 235 nm. RESULTS: The calibration curves were linear over the range of 0.25-16.0 mg.L^-1(r=0.999 9)for clopidogrel and 0.12548.0 mg.L^-1(r=0.999 6)for aspirin. The average recoveries were 98.3% and 99.6%, respectively. RSD of intra-day and inter-day validatin were all below 10%. CONCLUSION: The method is convenient, rapid, and sensitive for determination and analysis of clopidogrel and aspirin in human serum.
出处 《中国药房》 CAS CSCD 北大核心 2010年第2期122-124,共3页 China Pharmacy
基金 国家自然科学基金项目(30701040) 安徽省自然科学基金项目(070413117) 安徽省教育厅自然科学研究项目(2006KJ307B)
关键词 反相高效液相色谱法 氯吡格雷 阿司匹林 血药浓度 RP-HPLC Clopidogrel Aspirin Serum concentration
  • 相关文献

参考文献5

二级参考文献11

共引文献17

同被引文献42

  • 1胡维民,张文颖,程刚,邹梅娟.氯吡格雷片比格犬体内的药物动力学[J].中国药剂学杂志(网络版),2009(4):328-337. 被引量:3
  • 2Bode C, Zehender M. The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis[J]. Eur Heart J, 2007,9 ( Suppl D ) : D 10. 被引量:1
  • 3L' Allier PL, Ducrocq G, Pranno N, et al. Clopidogrel 600 mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study[J]. JAm Coll Cardiol, 2008, 51(11):1 066. 被引量:1
  • 4Mehta SR, Bassand JP, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7 : a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy[J]. Am Heart J, 2008,156(6) : 1 080. 被引量:1
  • 5Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement [J]. Circulation, 2006,113 (24) : 2 803. 被引量:1
  • 6Pallares MJ, Powers ER, Zwemer PL, et al. Barriers to clopidogrel adherence following placement of drug-eluting stents[J]. Ann Pharmacother, 2009,43 (2) : 259. 被引量:1
  • 7Roy P, Bonello L, Torguson R, et al. Impact of nuisance bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation[J]. Am d Cardiol, 2008,102(12) : 1 614. 被引量:1
  • 8Gurbel PA, Mahla E, Antonino M J, et al. Response variability and the role of platelet function testing[J]. J Invasive Cardiol , 2009 , 21( 2 ) : 172. 被引量:1
  • 9Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009,360 (4) : 354. 被引量:1
  • 10Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. NEnglJMed,2007,357(20):2 001. 被引量:1

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部